Short answer
Chemours Co (CC) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $1.6B (down 1.5% year over year) with net income of −$274M.
Q2 2026 key financials · XBRL
- Revenue
- $1.6B
- −1.5% YoY · +15.2% QoQ
- Net income
- −$274M
- +28.1% YoY · −844.8% QoQ
- Gross margin
- 18.0%
- EPS (diluted)
- −$1.82
- +28.1% YoY · −857.9% QoQ
Source: XBRL data from the Chemours Co (CC) Q2 2026 10-Q on SEC EDGAR. USD.
Chemours Co Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New regulatory risk: ECHA RAC recommended TFA as Reproductive Toxicity Category 1B and PMT/vPvM substance in June 2026
- Most material update: EU PFAS restriction evaluation now targets committee opinions by end-2026, with earliest restrictions in 2027
- Legal and compliance exposure: Fayetteville Consent Order remedies, including barrier wall and groundwater extraction, may exceed recorded reserves
- Operational risk: PFAS regulations could restrict product market access, trigger plant changes, or cause production interruptions
- Financial risk: Environmental liabilities may increase if U.S. PFAS drinking-water standards and CERCLA designations withstand court challenges
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Chemours Co quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.